49 results about "Mydriasis" patented technology

Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and / or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.

Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and / or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.

The invention provides a fundus camera optical system for detecting lesion of human eyes, and particularly provides a novel mydriasis-free portable fundus camera. The novel mydriasis-free portable fundus camera comprises a lighting system and an imaging system. The imaging system comprises an eye objective lens and an imaging objective lens, wherein the eye objective lens consists of first, second, third and fourth lenses from left to right, the imaging objective lens consists of fifth, sixth, seventh, eighth and ninth lenses, fundus is imaged on a CCD (Charge Coupled Device) by the imaging system and displayed in real time by an LCD (Liquid Crystal Display). The lighting system consists of an annular light source, a dodging lens and an eye objective lens, wherein the dodging lens consists of tenth, eleventh and twelfth lenses, and the eye objective lens and the imaging system are commonly used. PBS (Phosphate Buffer Solution) and a quarter wavelength plate are added in the system so as to eliminate the ghost image generated by the eye objective lens. According to the invention, the 2-megapixel CCD is adopted as the camera, the MTF (Mechanical Time Fuse) value is larger than 0.2 at a position of 120lp / mm, the full field angle is 60 degrees, the distortion value is smaller than 5%, and the fundus camera can be universally applicable to human eyes of minus 8D to positive 10D through adjusting the positions of the CCD.

A device and method are presented for drug-free, non-invasive, modulation of a size of a patient's pupil. The invention utilizes application of an external electric and / or magnetic field of desired properties to the patient's iris to thereby effect stimulation or neutralization of synapses and thus temporarily inducing mydriasis or miosis effect.

The invention is concerned with the method of preparation of the Mydriasis ophthalmic preparation. It is the kind of ophthalmic preparation that in liquid form before dripping into eyes but turns to gelatin postural after. It contents Mydriasis agent as the active material and other supplementary materials, such as poloxamer, carbomer, Deacetylcephalomannine Gellan Gum, transition regulator and medicinal acceptable antiseptic, isoosmotic adjustment, PH regulator and injection usage water. It can use of optometry, pre-operation naydriasis, etc. The advantages of the invention are: highly biocompatibility, low pungency, and long lasting.

The invention relates to a large-field-of-view fundus imaging device. The device comprises a device case, wherein a lighting module, an eye objective lens module, a field lens module, an imaging objective lens module and an imaging module are sequentially and coaxially mounted on the upper side inside the case from left to right, and a focusing module for adjusting the imaging module to move horizontally and axially is mounted below the imaging module. According to the imaging device, LEDs are used as lighting sources, the divergence angle is larger than 80 degrees, a uniform lighting field of view at 120 degrees is formed at the human eye fundus, USB3.0 data interfaces are adopted, color real-time image pickup at 20 frames per second can be performed on the fundus of a human eye after mydriasis, an image surface movement focusing mode is adopted, the overall light path structure is simplified, the device is reasonable in structure, and the size of equipment is greatly reduced.

The invention provides a mydriasis-free fundus camera used in conjunction with a smart phone. The camera comprises an optical path system, the smart phone, a control module and a mobile phone adapterenabling the optical path system to cooperate with the smart phone. The optical path system comprises lighting sources, a lighting objective lens group, an imaging objective lens group, a photoconverter and an ocular lens group. The lighting sources are characterized in that near infrared / visible light LEDs symmetrically rotate around the center and are arrayed in an alternating manner. The smartphone is used for shooting images which are reflected by human eyes and pass through the lighting objective lens group, the imaging objective lens group, the photoconverter and ocular lenses. The control module is used for controlling near infrared LED lamps of the lighting sources to emit light when the imaging objective lens group is adjusted to focus the fundus camera and for controlling visible light LED lamps of the lighting sources to emit light when human eyes are shot. During focusing, the near infrared LED lamps are adopted to illuminate so as not to simulate human eyes. Therefore, pupils of human eyes do not contract. During shooting, the visible light LED lamps are adopted and the photoconverter is utilized for enhancement. Therefore, human eye fundus images can be shot by thesmart phone in a mydriasis-free manner.

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

The invention discloses an eye ground imaging method based on Android. The eye ground imaging method includes the steps that when an eye ground image is photographed, an infrared light and an image preprocessing algorithm are used for positioning the pupil to find the optimal position for image photographing; when the photographing key is pressed, instant flashing and photographing are carried out to obtain the high-definition eye ground image. The default logic of photographing under dark light of Android is changed, mydriasis through drug smearing or high light illumination on the eye is not needed during photographing, damage to the eye by a traditional eye ground imaging method is effectively avoided, while operation is convenient, the high-definition image is obtained, and the eye ground condition of a user can be conveniently judged better.

The invention discloses a diabetic retinopathy screening method and device and a storage medium. The diabetic retinopathy screening method specifically comprises the steps that a deep convolution neural network model is built in advance through a series of methods including construction of a double-vision mydriasis-free fundus photography picture set, picture preprocessing, model design, model training and verification, and result judgment; when diabetic retinopathy results of a patient need to be screened, double-vision mydriasis-free fundus photography pictures of the to-be-screened patientare obtained, and then the pictures meeting quality requirements are input into the pre-constructed convolution neural network model so that diabetic retinopathy results can be easily and convenientlyobtained. Compared with the prior art, the screening method is simple, convenient to use and good in compliance, and also has the advantages of being high in accuracy, sensitivity and specificity.

The invention provides a portable non-mydriatic fundus imaging device. The device comprises an eyepiece and a relay lens assembly which are sequentially arranged in front of a to-be-tested eye, and the eyepiece is located between the to-be-tested eye and the relay lens assembly. An imaging polarizer is arranged on the imaging light-in side of the relay lens assembly and between the eyepiece and the relay lens assembly. An image sensor assembly is arranged on the imaging light-out side of the relay lens assembly. The eyepiece, the imaging polarizer, the relay lens assembly and the image sensor assembly are coaxially arranged. An illumination assembly is transversely arranged on one side of an optical axis in a deviated mode. The device has the advantages that under the condition that the to-be-tested eye is subjected to mydriasis without medicine, the to-be-tested eye can be observed in real time and subjected to video recording and flash photography. The device is mainly characterized in that high-definition imaging of the fundus of the to-be-tested eye is achieved by means of stray light, the host image subduction technology and the aberration correction technology on the premise that portability is maintained.

The invention relates to a traditional Chinese medicine composition for treating cataract, a prepration method thereof and a quality control method. The traditional Chinese medicine composition is composed of dendrobium, bitter orange, dwarf lilyturf tuber, baical skullcap root, cassia seed, liquoric root, cochinchnese asparagus root, twotooth achyranthes root, south dodder seed and other pharmaceutical raw materials, and excipients are added according to the conventional process to prepare tablets, capsules, dropping pills, pills, granules and other clinically acceptable formulations. The quality control method of the traditional Chinese medicine composition comprises the TLC identification of the dwarf lilyturf tuber, the south dodder seed and the Chinese magnoliavine fruit and the content measurement of baicalin in the baical skullcap root, and the method can effectively control the drug quality and ensure the efficacy of the drug. The drug has the effects of nourishing liver and kidney, benefiting qi and improving eyesight and has good effects for minute cataract, vision loss, mydriasis and senile cataract, impaired vision due to vitreous opacity, blowing in the wind and other symptoms.

Disclosed is a method for measuring the retinal blood vessel diameter and thickness of a vessel wall. The method is characterized by including: adopting an SD-OCT (spectral domain optical coherence tomography) scanning system for measurement and selecting all the retinal blood vessels in an area with the distance apart from the edge of an optical disc 0.5-1.0 times of the diameter of the optical disc as measuring objects through the SD-OCT system; allowing a scanning line to be perpendicular to the running direction of a positioning blood vessel to acquire a cross section figure of the retinal blood vessels; magnifying the scanned cross section figure of the blood vessels; moving a scale ruler to measure inner diameter and outer diameter of each blood vessel, wherein the thickness of the vessel wall=(the outer diameter-the inner diameter) / 2; calculating the central retinal artery equivalent Wt; taking the central retinal artery equivalent Wt=(0.87Wa<2>+1.01Wb<2>-0.22WaWb-10.73)<1 / 2> as a diagnostic basis. The method has the advantages of being free of damage, non-invasive, free of mydriasis and high in measurement precision.

The invention relates to a large-view-field mydriasis-free wide-refraction-compensation fundus imaging optical system. The large-view-field mydriasis-free wide-refraction-compensation fundus imaging optical system comprises an omentum objective lens group, a focusing lens group and an imaging lens group which are sequentially and coaxially arranged from left to right, and primary imaging is performed between the omentum objective lens group and the focusing lens group; the omentum objective lens group is formed by combining two balsaming lenses and a positive lens; the focusing lens group is composed of two meniscus lenses, and the focusing lens group adopts a stepping motor to drive an optical lens to perform accurate focusing according to a polynomial fitting curve; and the imaging lens group comprises two balsaming lenses in a quasi-symmetric form and a positive lens, and emergent light of the positive lens is vertically incident to an imaging focal plane. A secondary imaging system design is adopted, fundus large-view-field mydriasis-free imaging is achieved, and meanwhile stray light and ghost images can be eliminated; the minimum shooting pupil diameter is 2 mm, the imaging view field reaches up to 60 degrees, and diagnosis of eye diseases is facilitated; and the optical system is simple in structure, the installation and adjustment steps are simplified, each lens adopts a standard surface shape, and the processing is simple.

The invention discloses bendazol eye drops, which are prepared by mixing components including bendazol, sodium chloride, glycerol and ethylparaben and then adding water for injection. The bendazol eye drops can overcome the defects that cycloplegic used for mydriatic treatment in the traditional pseudomyopia treating manner at home and abroad causes reduced ciliary muscle tension, lasting mydriasis, phengophobia and lacrimation, photophobia discomfort and the like, and be directly dropped into eyes to relax smooth muscles (including ciliary muscles) and expand anterior ciliary arteries and veins, without mydriasis, so as to achieve a treatment function.

The invention provides an eye drop and its preparation, wherein the eye drop is prepared from the following medicaments (by volume proportion), 0.25% tropicamide eye drops 0.5-2, radix salvia miltiorrhiza injection 2-8, Guanosini triphosphas injection 0.5-2, carnine 0.5-2. The prepared eye drop has shown good effect for treating functional myopia for young people.

The present invention relates to preparation process of isocollidine preparation for eye. Through mixing isocollidine and inorganic acid or organic acid to form soluble isocollidine, dissolving in water, adding osmotic pressure regulator to osmotic pressure 280-320 mOsm / kg, adding hydrochloric acid or sodium hydroxide solution to regulate pH value to 3.0-7.0, adding water via stirring and sterilizing, solution for eye is obtained; or, gel as excipient is further added to obtain gel for eye. The isocollidine preparation for eye may be used to replace atropine, which has serious toxic side effect, for mydriasis, may be used also in regulating eyesight, treating pseudomyopia of teenage and eliminate eye fatigue, and is safe, effective and controllable.

The invention discloses compound eye drops used before an ophthalmologic operation and a preparing method thereof. The eye drops are prepared from, by weight, 5 mg / ml proparacaine hydrochloride, 5 mg / ml tropicamide, 5 mg / ml phenylephrine hydrochloride, 1-3 mg / ml sodium hyaluronate, buffer salt, isoosmotic adjusting agent, pH modifier and water for injection. By the adoption of the compound eye drops used before an ophthalmologic operation, mydriasis and surface anesthesia can be achieved, the workload of nurses is effectively relieved, and the working efficiency of nurses is improved.

The invention discloses an application of combined IFA and FFA to merged DR and DI. The application method includes the following steps that 1, eye mydriasis is dropped for 30 minutes with tropicamide eye drops; 2, patients are subjected to a sodium fluorescein allergy test; 3, patients free of allergy phenomenon are subjected to IFA inspection; 4, then the patients are subjected to FFA inspection; 5, IFA inspection is repeated; 6, FFA inspection is repeated. Combined IFA and FFA inspection is compared with a past separated IFA inspection and FFA, merged-DR-and-DI patients can be comprehensively evaluated through combined-IFA-and-FFA inspection in one time of inspection, and the one-time-IFA-inspection cost is saved for all the patients. More importantly, early-merged-DR-and-DI patients can be discovered through combined-IFA-and-FFA inspection, the basis is provided for individualized treatment accordingly, and it is prevented that the illness state is evolved to blind neovascular glaucoma from NPDI or PDI.

The invention discloses an optometry method suitable for myopia of children and teenagers. The method is to solve the problem that the existing optometry cannot achieve sufficient myopia degree, foot correction and clear retina imaging, and also cannot enable the glasses of children to be worn accurately and comfortably. The method comprises: 1, carrying out inquiry; 2, carrying out computer optometry, comprehensive optometry, trial optometry, adjustment training, computer optometry and trial optometry; 3, carrying out distant vision optometry and trial lens by using a comprehensive optometry unit after mydriasis; and 4, preparing a prescription: preparing glasses, and using the compound topicamide eye drops for patients with eye regulation tension in mydriasis. Adjustment training is added in the invention, so that sufficient myopia degree, foot correction and clear retina imaging are really realized, meanwhile, the glasses of children can be accurately and comfortably worn, the problem of dizziness and inadaptability is avoided, and obstacles are cleared for foot correction glasses matching; and, in addition, the problem of valuing before and after mydriasis is changed, and the diopter before mydriasis is adopted, so that foot correction optometry is really realized. The method is suitable for myopia optometry of children and teenagers.

The invention provides a cataract patient visual impairment degree evaluation system based on an AI technology. The cataract patient visual impairment degree evaluation system comprises an information acquisition module, a fundus image acquisition module, an image identification module, an image classification module, a disease condition evaluation module and a diagnosis and treatment suggestion module. Whether a patient suffers from cataract or not is automatically screened according to the fuzzy degree information in the mydriasis-free fundus image, and then the visual impairment degree of the fundus image marked with cataract is interpreted and graded, so that diagnosis and treatment suggestions are given in a targeted mode for patients with different degrees of visual impairment caused by cataract. According to the method, the relation between the severity of the cataract and the degree of visual impairment can be visually reflected, the accuracy of the evaluation result can be improved, and meanwhile, the process of screening the cataract through fundus photography has the advantages of being simple and rapid.

The invention provides a drug benzophenoxazines compound for treating cataract and a preparation method thereof. The chemical structural formula of the drug benzophenoxazines compound for treating thecataract is shown in the description. The provided drug benzophenoxazines compound is a mydriasis drug, is similar to a xanthommatin compound, can have stronger affinity with a crystalline lens soluble protein, can competitively inhibit the oxidation, degeneration and turbidity functions of quinoid substances on the crystalline lens soluble protein, prevent the development of the cataract, have good therapeutic effects on senile cataract, cataract caused by diabetes, traumatic and congenital cataract and retinitis pigmentosa, and can be used for further study and development of cataract diseases.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentol amine, for use in mono-therapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention discloses a portable non-mydriasis fundus camera, and relates to the field of medical ophthalmic optics instruments. The portable non-mydriasis fundus camera comprises an optical systemand a control unit, wherein the optical system comprises a positioning light path, a focusing light path and an illumination imaging light path; a group of vari-focus lens and an image sensor are shared by the positioning light path, the focusing light path and the illumination imaging light path; the positioning light path and the focusing light path respectively comprise one or more dual-opticalwedges; and the control unit is used for controlling the positioning light path, the focusing light path and the illumination imaging light path, and is used for performing treatment on the shot fundus images. The portable non-mydriasis fundus camera disclosed by the invention is small in volume, and convenient to carry, can also realize quick positioning of working distance and accurate focusing, and the photo forming quality and photo forming rate are simultaneously guaranteed; and a user can safely and conveniently use the portable non-mydriasis fundus camera.

The invention provides an eye ground camera device based on mobile equipment. The device comprises the mobile equipment and an optical component which are detachably connected. The optical component comprises an optical accessory, an illumination component and a coupling apparatus, wherein the optical accessory includes one partially-reflected surface; the illumination component is located at one end in an outer frame and is connected to an inner wall of the outer frame; a light direction of the illumination component faces towards the optical accessory and is vertical to a shooting direction of a camera of the mobile equipment; light of the illumination component is irradiated to the reflected surface and forms a reflected light beam pointing to eyes in a visual field of the camera; the coupling apparatus and the mobile equipment are detachably connected; and the coupling apparatus positions the optical accessory to a position corresponding to the camera of the mobile equipment. By using the eye ground camera device based on the mobile equipment, a common medical person and even a ordinary person who has one intelligent mobile phone can shoot without mydriasis and mydriatic eye ground; and a useful tool is provided for a wide range of eye ground screening and eye ground disease monitoring.